On August 23, 2020, the Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for convalescent plasma for the treatment of COVID-19.
Based on scientific evidence available, the FDA determined that it is reasonable to believe that COVID-19 convalescent plasma may be effective in lessening the severity or shortening the length of COVID-19 illness in some hospitalized patients. The agency also determined that the known and potential benefits of the product, when used to treat COVID-19, outweigh the known and potential risks of the product and that there are no adequate, approved, and available alternative treatments. The EUA authorizes the distribution of COVID-19 convalescent plasma in the U.S. and its administration by health care providers to treat suspected or laboratory-confirmed COVID-19 in hospitalized patients.
Food and Drug Administration (FDA). FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID–19 Treatment, Another Achievement in Administration’s Fight Against Pandemic [news release]. August 23, 2020. Available at: click here. Accessed August 24, 2020.